CN1582951A - Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels - Google Patents
Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels Download PDFInfo
- Publication number
- CN1582951A CN1582951A CN 200410046487 CN200410046487A CN1582951A CN 1582951 A CN1582951 A CN 1582951A CN 200410046487 CN200410046487 CN 200410046487 CN 200410046487 A CN200410046487 A CN 200410046487A CN 1582951 A CN1582951 A CN 1582951A
- Authority
- CN
- China
- Prior art keywords
- herba centellae
- total glycosides
- centellae total
- asiaticoside
- health product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A health-care food in the form of capsule, tablet, or oral liquid for preventing and treating cardiovascular and cerebrovascular diseases including coronary heart disease, angina pectoris, myocardial infarction, etc is prepared from the asiaticoside and additive.
Description
Technical field:
The present invention relates to the technical field of health product, specifically relate to a kind of with Herba Centellae total glycosides as functional factor, prepare the health product of a kind of auxiliary prevention and the treatment heart, cerebrovascular disease.
Background technology:
Herba Centellae Centella asiatica (L.) Urban is a Umbelliferae Centella plant, is distributed widely in various places on the south the Yangtze river basin.All herbal medicine.In China's Herba Centellae external and existing more than the 2000 year history of curing the disease for oral administration.It has clearing away heat-damp and promoting diuresis, the function of removing toxic substances and promoting subsidence of swelling.Be applicable to jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, injury from falling down.
The chemical constituent of Herba Centellae is based on triterpenes, as pentacyclic triterpene type ester glycosides such as asiaticoside (asiaticoside), asiaticoside (madecassoside), ripple hot-die glycosides (brahmoside), Bo Remi glycosides (brahminoside), thankuniside (thankuni-side), isothankuniside (isothankuniside), centelloside.Also contain some triterpene acids in the Herba Centellae, as: asiatic acid (asiatic acid), Madecassic acid (madecassic acid), Bo Remi acid (brahmic acid), madasiatic acid (madasiatic acid), centicacid, centoic acid, cenellic acid, indocentic acid etc.In addition, also have a spot of polyacetylene alkene class, volatile oil, beta-sitosterol, vanillic acid etc. in the Herba Centellae.
From content and active two aspects, Herba Centellae total glycosides is considered to pharmacological component and as the significant composition of Herba Centellae quality, mainly comprise two triterpene saponin of asiaticoside and asiaticoside (Chinese Chinese medicine information magazine, 2002,9 (8): 81-84).Asiaticoside molecular formula: C
48H
78O
19, molecular weight is 958.Asiaticoside molecular formula: C
48H
78O
20, molecular weight is 974.
The main pharmacologically active of Herba Centellae total glycosides has:
(1) to the effect of skin histology: Asiaticoside can promote wound healing, stimulates the granulation growth, promotes the epidermis keratinization, is used for the treatment of skin ulcer, as using in disease such as intractable wound, tuberculosis of skin, leprosy and the cosmetics for skin.By suppressing the synthetic of fibroblast proliferation and collagen protein, suppress cicatrization simultaneously.
(2) antibiotic: the in-vitro antibacterial experiment shows that Herba Centellae all has inhibitory action to golden yellow staphylococcus, haemolysis type streptococcus, various dysentery bacterium, Bacillus typhi.
(3) antiulcer: be used for the treatment of gastric ulcer.
(4) to central action: stimulate the central nervous system, be used for the treatment of depression, improve memory and resisting fatigue.Asiaticoside has spasmolytic, calmness, stable effect to mice and rat, mainly is the influence to cholinergic system among the central nervous system and gamma aminobutyric acid (GABA).
(5) alleviate the symptom that varicosis causes, this may have the structure of improving the blood vessel wall connective tissue and strengthen the venous function relevant with asiaticoside, is used for vein insufficiency of function (venous insufficiency).
(6) other: Herba Centellae total glycosides also has antiinflammatory, antioxidation, antitumor, treatment cyclomastopathy, anti-hepatic fibrosis, pulmonary fibrosis and renal fibrosis isoreactivity and purposes.
But do not see that Herba Centellae total glycosides is used to prevent and treat coronary heart disease such as angina pectoris, myocardial infarction and cerebrovascular such as cerebral thrombosis, the cerebral embolism report as health product.
Coronary heart disease be since the blood vessel-coronary artery of supply heart nutrient substance taken place atherosis due to.Atherosclerotic plaque coronarius can make the coronary artery tube chamber serious narrow even inaccessible, causes the blood flow of cardiac muscle to reduce, and the oxygen supply deficiency shows uncomfortable in chestly, feels suffocated angina pectoris, myocardial infarction even sudden death etc.The average at home prevalence of coronary heart disease is about 6.49%, and prevalence increases with age, thereby coronary heart disease is the modal a kind of cardiovascular disease of old people.The cause of coronary heart disease trend becomes younger at present, has become the commonly encountered diseases of middle-aged and elderly people.
Along with aged tendency of population, the cerebrovascular sickness rate constantly increases, and becomes one of healthy most important disease of harm humans.Die from the cerebrovascular patient and account for 11.3% in 57 countries of World Health Organization's investigation, wherein 40 national cerebrovascular account for cause of the death front three.World's average attack rate is 150～2,000,000/(100,000 population/year), and prevalence is 500～6,000,000/(100,000 population/year), and the whole world is by 5,000,000,000 people mental arithmetic, nearly 2500～30,000,000 patients.Die from the cerebrovascular patient more than heart disease and cancer in China, occupy three big cause of the death first places.The sickness rate of China's markization is 120～1,800,000/(100,000 population/year), prevalence is 4,290,000/(100,000 population/year), nearly 500～6,000,000 patients, wherein ischemic cerebrovascular occupies the majority, and comprises cerebral thrombosis, cerebral embolism, lacunar infarction and transient ischemic attack.Cerebral thrombosis, cerebral embolism have the characteristics of high incidence, high disability rate and high relapse rate, cause a large amount of group of handicapped, have brought heavy society and financial burden.
Health food has the function of preventing and treating disease activity, and is easy to use, no obvious toxic and side effects.Herba Centellae total glycosides, main active are asiaticoside and asiaticoside, and rats by intraperitoneal injection 2g/kg is not dead, and the oral 1g/kg of mice and rabbit can tolerate, and show that Herba Centellae total glycosides is nontoxic substantially.In addition, Herba Centellae is that the Ministry of Public Health approval can be used for one of Chinese herbal medicine of health food (Chinese food health magazine, 2002,14 (3): 59).The generation of cardiovascular and cerebrovascular disease and development have individual process.Before manifest symptom occurring, prevention has important value to the cardiovascular and cerebrovascular disease firsts and seconds to adopt health food.
Summary of the invention:
The object of the invention is Herba Centellae total glycosides to prepare the health product of a kind of assisting in preventing and treating heart, cerebrovascular disease as functional factor.
Herba Centellae total glycosides of the present invention, main active ingredient is asiaticoside and asiaticoside.In the cardiovascular and cerebrovascular disease model, therefore asiaticoside and asiaticoside active close need not further with asiaticoside and asiaticoside separately, need not also that the ratio between the two class glycosides can obtain satisfied curative effect in the further clear and definite total glycosides.
In the present invention, the health product of the control heart, cerebrovascular disease, the Herba Centellae total glycosides that contains 0.4-40% is equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component; Be preferably the Herba Centellae total glycosides that contains 1-30% and be equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component, can select to be the Herba Centellae total glycosides that contains 5-25% be equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component.
In the present invention, in the described Herba Centellae total glycosides content sum of asiaticoside and asiaticoside more than or equal to 40%.Possible is to surpass 60%, is preferably to surpass 80%.
When oral agents is a capsule, every heavy 0.25-0.35 gram of capsule contains Herba Centellae total glycosides 10-40%, pharmaceutic adjuvant 60-90%; Oral agents is a tablet, and every weight is the 0.15-0.25 gram, contains Herba Centellae total glycosides 10-40%, pharmaceutic adjuvant 60-90%.Oral agents is an oral liquid, contains Herba Centellae total glycosides 0.4-2%, natural sweetener 15-25%, and all the other are water.
In the present invention, adjuvant that described food and medicine allowed and/or additive can be:
(1) frumentum; Starch; Dextrin;
(2) vegetable puree;
(3) sweeting agent-stevioside or protein sugar, or Xylitol etc.;
(4) essence;
(5) carboxymethyl cellulose;
(6) arabic gum etc.
The present invention extracts the processing step of Herba Centellae total glycosides from Herba Centellae as follows:
(1) Herba Centellae is pulverized the back and use 75% alcohol reflux, 2 hours totally 3 times;
(2) reclaim ethanol and get extractum;
(3) extractum adds deionized water dissolving;
(4) above-mentioned water-soluble liquid is decoloured by decolorizing resin, collect effluent, the reuse alcoholic solution is collected ethanol elution after by this decolorizing resin, merges above-mentioned effluent and ethanol elution;
(5) liquid of above-mentioned merging is evaporated to dried, thick thing;
(6) with the above-mentioned thick thing of dissolve with methanol, ratio is thick thing (kg): the volume of methanol (ml)=1: 100～500 get Herba Centellae total glycosides solution;
(8) with above-mentioned Herba Centellae total glycosides solution ethyl acetate crystallization, ratio is the volume (ml) of Herba Centellae total glycosides solution: the volume of ethyl acetate (ml)=1: 1～100.Be evaporated to according to a conventional method dried, the white powder Herba Centellae total glycosides.Detect institute with the standard substance of asiaticoside and asiaticoside and HPLC method and carry the content of avenging asiaticoside and asiaticoside in the careless total glycosides.The Herba Centellae total glycosides of gained, wherein the content of asiaticoside and asiaticoside surpasses more than 40%, can satisfy the requirement of preparation control cardiotropic formulation.
The functional activity testing program and the result of Herba Centellae total glycosides are as follows:
(1) utilizes isolated rat heart anoxia/reperfusion injury model, give Herba Centellae total glycosides 5mg/kg, 10mg/kg, Asiaticoside or each 5mg/kg of madecassoside, coronary flow is obviously increased, heart rate remains unchanged or slows down, the heartbeat rule, infarct size is obviously dwindled, and drops to 10.9% of Herba Centellae total glycosides 10mg/kg group from 33.7% of matched group, and effect is very remarkable.
(2) utilize ligation rat arteria coronaria to cause the acute myocardial infarction pathological model, observe the protection cardiac muscle effect of asiaticoside and asiaticoside.Found that, 1h gavages Herba Centellae total glycosides 20mg/kg, 40mg/kg Asiaticoside or each 20mg/kg of madecassoside, 20mg/kg before the ligation, heart rate all slows down to some extent before making behind the coronary ligation rat than ligation, the rat electrocardiogram descends as S-T section, T ripple, creatine kinase in the rat blood serum (CK), lactic acid dehydrogenase (LDH) value all reduce than matched group, and myocardial infarction area is had the effect of significantly dwindling.Myocardial infarction area drops to 13.6% of Herba Centellae total glycosides 40mg/kg group, effect highly significant from 36.5% of matched group.
(3) utilize ligation dog M-LAD to cause dog myocardial infarction model, observe the anti-myocardial infarction effect of asiaticoside and asiaticoside.Found that Herba Centellae total glycosides can obviously reduce the myocardial infarction district weight that the ligation arteria coronaria causes, and relatively descends 49.2% with matched group, make the biochemical metabolism index LDH and the active obviously decline of CK of reflecting myocardium damage range simultaneously.
(4) utilize rat acute focal cerebral ischemia model to observe the curative effect of Herba Centellae total glycosides.There is the small pieces quantitative filter paper of 50% liquor ferri trichloridi (1mol/L hydrochloric acid) to spread on preparation cerebral thrombosis model on the intraluminal middle cerebral artery occlusion in rats suction.Successive administration is 3 days before the modeling, and laboratory animal is divided into: normal control group, model control group, Herba Centellae total glycosides 20mg/kg, Herba Centellae total glycosides 40mg/kg, asiaticoside 20mg/kg group, asiaticoside 20mg/kg group.Found that Herba Centellae total glycosides, asiaticoside and asiaticoside all can obviously dwindle brain infarction area, can obviously reduce the water content of middle cerebral artery thromboembolism rat brain.
In the present invention, if not refer in particular to, all amounts, part and percentage ratio are unit of weight, and all equipment and raw material etc. all can be buied from market or the industry is commonly used.
Below in conjunction with embodiment in detail the present invention is described in detail, can not limits the scope of the invention but embodiment only is used for explanation.
The specific embodiment
The preparation of embodiment 1 Herba Centellae total glycosides
Get 1 kilogram of fresh dried Herba Centellae and pulverize, the 75% ethanol elder generation soaked overnight with 3 liters refluxed 2 hours again, carried out altogether 3 times, reclaimed ethanol, and conventional concentrating under reduced pressure gets extractum.Extractum is added 3 liters of deionized water dissolving, again water-soluble liquid is added to decolorizing resin, collect effluent, reuse 60% alcoholic solution is collected ethanol elution after by this decolorizing resin, merges above-mentioned effluent and ethanol elution.With the liquid concentrating under reduced pressure of above-mentioned merging as for, thick thing.With 500 milliliters of above-mentioned thick things of analytical pure dissolve with methanol, get Herba Centellae total glycosides solution.The crystallization of 4 liters of analytical pure ethyl acetate of reuse in 40 ℃ of vacuum dryings, obtains 21.1 gram white powder solids.
The preparation of embodiment 2 capsules
Herba Centellae total glycosides raw material 300 grams, medical starch 1000 grams stir, the capsule of packing into No. 0, every 0.3 gram, each oral 2, every day 1-3 time.
Embodiment 3 preparation tablets
Herba Centellae total glycosides raw material 200 grams, medical starch 1000 grams stir, and use an amount of alcohol granulation, through granulate, tabletting, every 0.2 gram, oral, each 2, every day 1-3 time.
The preparation of embodiment 4 oral liquids
Herba Centellae total glycosides raw material 5 grams add a small amount of dissolved in distilled water, add stevioside 20 grams again, and adding distil water is to volume 1000ml while stirring, and embedding is sterilized promptly.Every 10ml, each 1, every day 1-2 time.
The preparation of embodiment 5 oral liquids
Herba Centellae total glycosides raw material 10 grams add a small amount of dissolved in distilled water, add stevioside 15 grams again, and adding distil water is to volume 1000ml while stirring, and embedding is sterilized promptly.Every 10ml, each 1, every day 1-2 time.
The preparation of embodiment 6 electuaries
Herba Centellae total glycosides raw material 10% adds stevioside and other adjuvant 90%, stirs, and granulates through 20 mesh sieves, and freezing, drying is respectively charged in the small plastic bag, every bag 40 gram, and radiation sterilization.Described adjuvant is selected from starch, dextrin, essence etc.
The preparation of embodiment 7 health-care cake (or cake)
(1) prescription: (a) the Herba Centellae total glycosides raw material 5%, flour 93%, sweeting agent 2%;
(b) the Herba Centellae total glycosides raw material 10%, flour 54%, Semen Maydis powder 35%, sweeting agent 1%;
(c) the Herba Centellae total glycosides raw material 15%, flour 53.5%, Fagopyrum esculentum Moench powder 30%, sweeting agent 1.5%.
(2) method for making: by the requirement of dietetic therapy (health care) effect, choose one of above-mentioned prescription respectively, mix thoroughly after taking by weighing, adding edible sodium bicarbonate and water are an amount of, rub into dough, place 1-2 hour (when room temperature is lower than 15 ℃, placed 2 hours), drop into dough in the make-up machine or the cake or the cake base of the different shape that is made by handwork, with the base sabot or go into the stove baking, or upward cage cooks, about 30 minutes.
The preparation of embodiment 8 healthy fine dried noodles
Herba Centellae total glycosides raw material 2%, all the other are flour and a small amount of adjuvant, with warm water the Herba Centellae total glycosides raw material are dissolved earlier, with flour mixing stirring, knead then, pressure surface enters drying chamber and hangs dried.Drying course adopts low temperature to decide bar, hyperthermia drying, sub-cooled three phases.It after the cooling molding.Be packed as the fine dried noodles product of 70-100 gram one bag.Adjuvant is various flavoring agent, adds lactic acid calcium powder 0.1-2g in each parcel.
Embodiment 9 Herba Centellae total glycosidess are to the influence of isolated rat heart anoxia/reperfusion injury
Wistar cleans rat, and is male, body weight 200-240g.Herba Centellae total glycosides prepares voluntarily, and reference substance asiaticoside (purity is greater than 95%) and asiaticoside (purity is greater than 95%) are available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.Herba Centellae total glycosides and hydroxyl amass careless glycosides physiological saline solution, the asiaticoside anhydrous alcohol solution, and the dilution of reuse normal saline, the ethanol final concentration is 0.1% (V/V).Red tetrazolium (TTC) is produced by Shanghai reagent three factories, potassium phosphate buffer (pH7.8) autogamy, heparin sodium injection, the Shanghai first biochemical Pharma Inc., lactic acid dehydrogenase (LDH) test kit, creatine phosphokinase (CK) test kit are produced by Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..The Langendorff perfusion device, Japanese photoelectricity electrocardiograph, SABA-18 automatic clinical chemistry analyzer.
Get the rat that body weight is 200-240g, lumbar injection 500U/kg anticoagulant heparin, inject amobarbital sodium (30mg/kg) anesthesia behind the 15min, opening the thoracic cavity rapidly, expose heart, break pericardium, mention gently after isolating heart, cut with the elbow tissue in aortic root 5-7mm place and cut off superior and inferior vena cava rapidly, pulmonary artery, aorta and heart surrounding tissue extract heart, place the K-H liquid of pre-cooling (4 ℃), push heart gently with finger, make residue blood discharge in the heart, artery-clogging is fixed in aorta on the sleeve pipe of perfusion device with silk thread in case the hemostasis-coagulation piece forms.Perfusion drives in the wrong direction with 37.5 ℃ perfusate constant voltages (pressure altitude is the 75cm water column).Krebs-Henseleit (K-H) balanced natritive liquid, constituent is (mmol/L): NaCl118, KCl4.63, MgCl
21.2, CaCl
24.8, NaHCO
325, KH
2PO
41.17 glucose 11.0 feeds 95%O with nutritional solution earlier before the experiment
2And 5%CO
2Gaseous mixture 10min carry out fully saturatedly, throughput is 1.0L/min, pH7.4.In experimentation, heart is placed in the glass cell to remain in 38 ± 1 ℃ the external environment.Cut off heart adhering tissue on every side, cut off an osculum in pulmonary artery initial part and circular cone position, right ventricle, help the discharge of arteria coronaria backflow, measuring effluent with measuring graduate is coronary flow.Regularly collect the arteria coronaria effluent, record 1min coronary flow (CF) is with the lactic acid dehydrogenase (LDH) and creatine phosphokinase (CK) content of full automatic biochemical apparatus mensuration effluent.Insert platinum electrode in left ventricle portion and right atrium portion respectively, trace electrocardiogram II and lead, be used to observe heart rate (HR), S-T section, T ripple, R ripple, the Q-T variation of interval.The retrograde perfusion 10min of heart is an equilibration time, utilize constant flow pump that 5ml normal saline or medicinal liquid (1mg or the 2mg dose) speed with 0.5ml/min is poured in the heart with perfusate, wear No. 000 silk thread in the anterior descending coronary root behind the administration 10min, together with the ligation of 1mm diameter sticking plaster, take out sticking plaster behind the 30min, make the logical again 60min of cardiac muscle of anterior descending coronary domination.After experiment finishes, heart taken off be cut into thick 5 of 0.1cm, myocardium sheet is placed in 1% the TTC phosphate buffer solution, pH 7.8, incubate 15min 37 ℃ of temperature, and normal myocardium dyes and is redness, the cardiac muscle of infarcted region is not painted or shallow painted, after the dyeing myocardium sheet is put into 10% formalin and fixes.Take by weighing whole-heartedly with electronic balance heavy, again clip not colour attaching area (infarcted region cardiac muscle) weigh the calculating myocardium infarct size.Heavy (mg) * 100% of myocardial infarction area (%)=infraction heavy (mg)/whole-heartedly.
Found that Herba Centellae total glycosides can make coronary flow increase, wherein increase obviously,, show the activity of the anti-myocardial infarction of Herba Centellae total glycosides all than matched group height (table 1) with Herba Centellae total glycosides 10mg/kg dosage group and asiaticoside, asiaticoside.
The influence that coronary flow changed due to table 1 Herba Centellae total glycosides poured into the isolated rat heart anoxia again
Group dosage coronary flow (ml/min)
Mg/kg balance period administration phase 5min administration phase 10min L15min L30min R15min R30min
Matched group-10.1 ± 1.6-8.6 ± 1.8 6.6 ± 1.4 5.9 ± 1.0 7.3 ± 1.8 6.4 ± 2.0
Herba Centellae total glycosides 5 9.2 ± 1.2 10.5 ± 2.0 10.2 ± 1.2
*8.5 ± 1.5
*9.0 ± 1.5
*8.2 ± 2.g 7.8 ± 1.2
Herba Centellae total glycosides 10 9.5 ± 1.5 11.2 ± 1.8 10.6 ± 2.1
*9.5 ± 1.0
*9.8 ± 1.2
*9.0 ± 1.0
*8.8 ± 1.8
*
Asiaticoside 5 11.0 ± 2.0 11.5 ± 2.5 9.5 ± 2.5
*9.2 ± 1.8
*9.2 ± 1.2
*9.0 ± 2.5
*8.5 ± 2.0
*
Asiaticoside 5 12.5 ± 0 11.0 ± 2.0 9.8 ± 2.2
*9.5 ± 1.5
*8.0 ± 2.0
*8.0 ± 2.1
*8.2 ± 2.8
*
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01.L: ligation; R: irritate again
After giving Herba Centellae total glycosides, asiaticoside and asiaticoside, each is organized heart rate and all slightly slows down to some extent.Ligation and irritate back matched group heart heart rate slack-off (table 2) again.Herba Centellae total glycosides and asiaticoside, asiaticoside can make heart rate accelerate or keep normal.
The influence of changes in heart rate due to table 2 Herba Centellae total glycosides pours into the isolated rat heart anoxia again
Group dosage heart rate (inferior/min)
Mg/k balance period administration L30min R15min R30min R60min
g 10min
Matched group-246 ± 42 224 ± 40 184 ± 54 181 ± 25 191 ± 34 173 ± 52
Herba Centellae total glycosides 5 237 ± 34 222 ± 41 211 ± 92 210 ± 60 210 ± 56 200 ± 64
Herba Centellae total glycosides 10 250 ± 40 232 ± 25 216 ± 22
*225 ± 29 239 ± 18
*228 ± 51
Asiaticoside 5 243 ± 18 210 ± 30 232 ± 25
*233 ± 70
*224 ± 68 250 ± 33
Asiaticoside 5 237 ± 48 220 ± 40 237 ± 82
*294 ± 114
*257 ± 47
*228 ± 93
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01.L: ligation; R: irritate again
Herba Centellae total glycosides, asiaticoside and asiaticoside all can make myocardial infarction area dwindle (table 3), and the Herba Centellae total glycosides high dose group is similar with asiaticoside group effect to the asiaticoside group.
The influence of myocardial infarction area due to table 3 Herba Centellae total glycosides pours into the isolated rat heart anoxia again
Group dosage (mg/kg) is weight in wet base (mg) infarcted region weight in wet base (mg) myocardial infarction area % whole-heartedly
Matched group-720.3 ± 68.2 247.8 ± 84.9 33.7 ± 9.3
Herba Centellae total glycosides 5 680.2 ± 33.9 100.5 ± 25.7
*17.9 ± 6.9
*
Herba Centellae total glycosides 10 605.5 ± 21.9 77.5 ± 19.2
* *10.9 ± 3.6
* *
Asiaticoside 5 674.2 ± 24.1 70.8 ± 39.8
* *9.4 ± 3.0
* *
Asiaticoside 5 634.4 ± 34.1 72.2 ± 24.2
* *10.1 ± 2.2
* *
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
Embodiment 10 Herba Centellae total glycosidess cause the influence of acute myocardial infarction to the ligation rat coronary artery
Wistar cleans rat, and is male, body weight 200～240g.Reference substance asiaticoside (purity is greater than 95%) and asiaticoside (purity is greater than 95%) are available from Nat'l Pharmaceutical ﹠ Biological Products Control Institute.Red tetrazolium (TTC) is produced by Shanghai reagent three factories; potassium phosphate buffer (pH7.8) autogamy; pentobarbital sodium, Shanghai chemical reagents corporation, lactic acid dehydrogenase (LDH) test kit, creatine phosphokinase (CK) test kit are produced by Zhongsheng Beikong Biological Science ﹠ Technology Co., Ltd..Experimental apparatus: HXQ-1 artificial respirator, Japanese photoelectricity electrocardiograph, SABA-18 automatic clinical chemistry analyzer, IEC centrifuge.
Get 200～240g rat, grouping: 1. model control group; 2. Herba Centellae total glycosides 20mg/kg organizes, 3. Herba Centellae total glycosides 40mg/kg organizes.2. asiaticoside 20mg/kg organizes, 3. asiaticoside 20mg/kg organizes.Gavage administration with 1% sodium carboxymethyl cellulose mixing, after 1 hour, pentobarbital sodium (30mg/kg) abdominal cavity light anaesthesia, back of the body position is fixing.Be connected to artificial respirator with more than half rubber bulb (size is just in time entangled the rat incidence), practice artificial respiration.Chest unhairing, sterilization, along the about 2cm of left mid-clavicular line longitudinal incision skin, separate the flesh layer in the 4th or the 5th intercostal passivity, open the thoracic cavity, cut off pericardium, gently press the right side thorax, extrude heart.Behind ligation anterior descending branch in Coronary vein place between arterial cone and the left auricle, heart is put back to the thoracic cavity.Close the thoracic cavity rapidly, stop the artificial respiration, push chest gently, make heartbeat recover normal, place in the cage for animal and observe with forefinger and thumb.Before using electrocardiograph to write down ligation respectively, 2h, 4h, 6h electrocardiogram after the ligation are used to observe the S-T section and change.Ligation 6 hours after pentobarbital sodium (30mg/kg) abdominal cavity light anaesthesia, is opened the abdominal cavity, extract 5ml venous blood from postcava, use centrifuge, centrifugal 20 minutes with 3000 rev/mins, get serum, utilize full automatic biochemical apparatus to measure the content of serum lactate dehydrogenase (SLD) (LDH) and creatine phosphokinase (CK).After experiment finishes, the rat heart taking-up is placed in the cardiac muscle section mould, be cut into thick 5 of 0.1cm and put into 1% TTC phosphate buffer solution, pH7.8, incubate 15min 37 ℃ of temperature, normal myocardium dyes and is redness, and the cardiac muscle of infarcted region is not painted or shallow painted, after the dyeing myocardium sheet is put into 10% formalin and fix, take the myocardial infarction shade.Take by weighing whole-heartedly heavy, Zuo Xinchong with electronic balance, again clip not colour attaching area (myocardial infarction district) weigh the calculating myocardium infarct size.
Heavy (mg)/whole-heartedly flesh of muscle infarction area (%)=infraction weighs (mg) * 100% whole-heartedly
Left side myocardial infarction area (%)=infraction heavy (mg)/heavy (mg) * 100% of left side cardiac muscle
Found that Herba Centellae total glycosides, asiaticoside and asiaticoside all have the decline effect to heart ligation arteria coronaria rat S-T section, wherein at ligation 2h and 4h comparatively obviously (table 4).
The influence that table 4 Herba Centellae total glycosides changes S-T section due to the rat heart ligation arteria coronaria
Group dosage number of animals S-T section is raised (mm)
Ligation 2h ligation 4h ligation 6h before mg/kg (only) ligation
Matched group-6 0 3.1 ± 1.5 1.2 ± 0.7 1.2 ± 1.0
Herba Centellae total glycosides 20 60 2.0 ± 1.3
*1.0 ± 0.4 0.9 ± 0.6
Herba Centellae total glycosides 40 60 1.4 ± 0.4
*0.8 ± 0.3
*0.7 ± 0.2
*
Asiaticoside 20 60 1.2 ± 0.4
* *0.4 ± 0.2
*0.8 ± 0.4
Asiaticoside 20 60 1.1 ± 1.8
*0.5 ± 0.3
*0.5 ± 0.3
*
Annotate: with the matched group ratio,
*P＜0.05,
*P＜0.01,
* *P＜0.001.
CK, LDH value are all than matched group low (table 5) in Herba Centellae total glycosides high dose group, asiaticoside group and the asiaticoside group rat blood serum.
The influence that table 5 Herba Centellae total glycosides changes CK, LDH value due to the rat heart ligation arteria coronaria
Group dosage number of animals LDH (U/L) CK (U/L)
(mg/kg)
Matched group-6 1727.3 ± 205.7 4216.6 ± 443.5
Herba Centellae total glycosides 20 6 1510.1 ± 203.2 3420.1 ± 430.4
Herba Centellae total glycosides 40 6 1203.4 ± 210.2
*2451.4 ± 203.6
*
Asiaticoside 20 6 1152.2 ± 122.6
*2153.2 ± 1127.8
*
Asiaticoside 20 6 1101.3 ± 224.2
*2082.5 ± 786.8
*
Annotate: with the matched group ratio,
*P＜0.05.
Herba Centellae total glycosides, asiaticoside and asiaticoside have the effect significantly dwindled (table 6) to heart ligation arteria coronaria rat model myocardial infarction area.
Table 6 Herba Centellae total glycosides is to the influence of myocardial infarction area due to the rat heart ligation arteria coronaria
Group dosage number of animals myocardial infarction area (%)
(mg/kg) (only) accounts for the left ventricle area and accounts for the left ventricle area
Matched group-6 36.5 ± 3.5 31.4 ± 2.2
Herba Centellae total glycosides 20 6 20.1 ± 2.7
*19.2 ± 2.1
*
Herba Centellae total glycosides 40 6 13.6 ± 3.2
*13.2 ± 1.9
*
Asiaticoside 20 6 14.6 ± 4.0
*12.8 ± 3.5
*
Asiaticoside 20 6 14.9 ± 3.6
*12.8 ± 2.9
*
Annotate: compare with matched group,
*P＜0.05,
*P＜0.01,
Embodiment 11 Herba Centellae total glycosidess are to the influence of dog acute myocardial infarction
Make and select 36 of healthy adult domesticated dogs, the male and female dual-purpose, overnight fasting is divided into 6 groups at random, 6 every group.Grouping and dosage see Table.Gavage administration after 3 hours with domesticated dog with urethane anesthesia and be fixed in operating-table, circulation of qi promoting cannula art connects artificial respirator, the 4th intercostal is opened breast and is exposed heart in the left side then, cuts off pericardium and ligation M-LAD.After 6 hours, get the activity of hematometry LDH and CK; Take out and weigh whole-heartedly and crosscut becomes the plurality of thin piece, put 1% triphenyltetrazolium chloride (TTC) solution into and make specimen dyeing 10min substantially, normal myocardium is dyed is peony, and infarcted region is not painted.Carefully cut non-staining cardiac muscle and weigh, the calculating myocardium infarction partly accounts for the percentage ratio of weight whole-heartedly, sees Table 1.The result shows that Herba Centellae total glycosides can obviously dwindle the myocardial infarct size that the ligation arteria coronaria causes, and makes the biochemical metabolism index LDH and active obviously descend (table 7) of CK of reflecting myocardium infarction damage range simultaneously.
Table 7 Herba Centellae total glycosides is to the influence of dog myocardial infarction due to the coronary ligation
Group dosage infarcted region percentage by weight LDH (U/L) CK (U/L)
Normal saline-20.1 ± 4.3 387.3 ± 23.2 121.2 ± 23.1
Herba Centellae total glycosides 10mg/kg 12.3 ± 4.2
*301.1 ± 32.1
*89.0 ± 12.1
*
Herba Centellae total glycosides 20mg/kg 10.2 ± 2.6
*254.1 ± 26.9
*72.1 ± 15.8
*
Asiaticoside 10mg/kg 8.8 ± 3.2
*236.9 ± 21.1
*70.1 ± 16.5
*
Madecassoside 10mg/kg 8.4 ± 2.6
*220.1 ± 25.7
*68.9 ± 19.2
*
1.5/kg of FUFANG DANSHEN PIAN 13.1 ± 3.8
*289.0 ± 21.9
*82.1 ± 17.9
*
Annotate: compare with the normal saline matched group,
*P＜0.05,
*P＜0.01
Embodiment 12 Herba Centellae total glycosidess are to the influence of rat acute focal cerebral ischemia
The Wistar rat, male, body weight 210 ± 20 grams.Secondary.Being divided into 2 batches carries out.Reagent chloro triphenyltetrazolium chloride (TTC) Beijing Chemical Plant produces.Every batch of animal is divided into 8 groups at random by body weight: normal control group, model control group, Herba Centellae total glycosides 20mg/kg, Herba Centellae total glycosides 40mg/kg, asiaticoside 20mg/kg group, asiaticoside 20mg/kg group.Every group 12.Irritate stomach by body weight and give each medicinal liquid 0.5ml/100g body weight, normal control group and model control group give equal-volume normal saline water, and all successive administration is 3 days.1h behind the 2nd day medicine, pentobarbital sodium (35mg/kg) intraperitoneal injection of anesthesia.Press literature method, expose rat right side middle cerebral artery, have the small pieces quantitative filter paper of 50% liquor ferri trichloridi (1mol/L hydrochloric acid) to spread on the middle cerebral artery suction,, sew up wound with taking off filter paper after the anatomic microscope observation thrombosis.Matched group covers the ferric chloride filter paper the same model group of all the other operating procedures except that not applying.23h gastric infusion 1 time again after the modeling.24h after modeling, broken end is got brain.The mensuration of cerebral infarct size: rat broken end back is taken out full brain rapidly, removes olfactory bulb, cerebellum and low brain stem, and remainder is crown under 4 ℃ to be cut into 5.(every 5ml dye liquor contains 4%TTC 1.5ml, 1mol/L K rapidly the brain sheet to be placed the TTC dye liquor
2HPO
40.1ml), 37 ℃ of lucifuge temperature are incubated 30min, take out to be placed in 10% formalin to keep in Dark Place.The non-ischemic region in dyed back is a rose, and infarct is a white.The white tissue is weighed careful the separation, account for the percentage ratio of total brain weight as cerebral infarct size with blocking tissue's weight.The mensuration of brain water content: rat broken end back is taken out full brain rapidly, gets right half brain ball, claims weight in wet base, and 110 ℃ of oven dry 24h claim dry weight, calculate brain water content.
Found that Herba Centellae total glycosides, asiaticoside and asiaticoside all can obviously dwindle brain infarction area, can obviously fall the brain water content that the middle cerebral artery thromboembolism causes.
Table 8 Herba Centellae total glycosides is to the influence of rat acute focal cerebral ischemia
Group dosage (mg/kg) animal brain infarct size (%) brain water content (%)
Normal control-10 0.01 ± 0.002 77.1 ± 0.4
Model contrast-10 5.12 ± 1.34# 80.1 ± 1.4#
Herba Centellae total glycosides 20 10 3.14 ± 1.21
*79.5 ± 1.2
Herba Centellae total glycosides 40 10 2.12 ± 1.29
*78.1 ± 2.1
*
Asiaticoside 20 10 2.34 ± 1.22
*78.0 ± 1.5
*
Madecassoside 20 10 2.46 ± 1.09
*79.1 ± 1.3
*
Annotate: compare #P＜0.05 with the normal control group; Compare with model control group,
*P＜0.05,
*P＜0.01
The health products that contain asiaticoside provided by the invention can play the protection cardiovascular and cerebrovascular, the effect that delays senility, And function is definite, and taking convenience is for mid-aged population provides a kind of novel, reliable health products, to improving people's Quality of life has useful effect.
Claims (8)
- The health product of 1 one kinds of assisting in preventing and treating hearts, cerebrovascular disease, the Herba Centellae total glycosides that it is characterized in that containing 0.4-40% is equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component.
- The health product of the 2 control hearts according to claim 1, cerebrovascular disease, the Herba Centellae total glycosides that it is characterized in that containing 1-30% is equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component.
- The health product of the 3 control hearts according to claim 1, cerebrovascular disease, the Herba Centellae total glycosides that it is characterized in that containing 5-25% is equipped with food or the pharmaceutically acceptable oral agents that adjuvant that food and medicine allow and/or additive are made as active component.
- 4 according to the described health product of one of claim 1-3, and the content sum that it is characterized in that asiaticoside and asiaticoside in the described Herba Centellae total glycosides is more than or equal to 40%.
- 5 according to the described health product of one of claim 1-3, it is characterized in that oral agents is a capsule, and every heavy 0.25-0.35 gram of capsule contains Herba Centellae total glycosides 10-40%, pharmaceutic adjuvant 60-90%.
- 6 according to the described health product of one of claim 1-3, it is characterized in that oral agents is a tablet, and every weight is the 0.15-0.25 gram, contains Herba Centellae total glycosides 10-40%, pharmaceutic adjuvant 60-90%.
- 7 according to the described health product of one of claim 1-3, it is characterized in that oral agents is an oral liquid, contain Herba Centellae total glycosides 0.4-2%, natural sweetener 15-25%, and all the other are water.
- 8 according to the described health product of one of claim 1-7, it is characterized in that described Herba Centellae total glycosides is to adopt to be prepared as follows method and to make from Herba Centellae:(1) Herba Centellae is pulverized the back and use 75% alcohol reflux, 2 hours totally 3 times;(2) reclaim ethanol and get extractum;(3) extractum adds deionized water dissolving;(4) above-mentioned water-soluble liquid is decoloured by decolorizing resin, collect effluent, the reuse alcoholic solution is collected ethanol elution after by this decolorizing resin, merges above-mentioned effluent and ethanol elution;(5) liquid of above-mentioned merging is evaporated to dried, thick thing;(6) with the above-mentioned thick thing of dissolve with methanol, ratio is thick thing (kg): the volume of methanol (ml)=1: 100～500 get Herba Centellae total glycosides solution;(7) with above-mentioned Herba Centellae total glycosides solution ethyl acetate crystallization, ratio is the volume (ml) of Herba Centellae total glycosides solution: the volume of ethyl acetate (ml)=1: 1～100.Be evaporated to according to a conventional method dried, the white powder Herba Centellae total glycosides.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100464873A CN100531740C (en) | 2004-06-10 | 2004-06-10 | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100464873A CN100531740C (en) | 2004-06-10 | 2004-06-10 | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1582951A true CN1582951A (en) | 2005-02-23 |
| CN100531740C CN100531740C (en) | 2009-08-26 |
Family
ID=34602005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100464873A Expired - Fee Related CN100531740C (en) | 2004-06-10 | 2004-06-10 | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100531740C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389437A (en) * | 2011-06-24 | 2012-03-28 | 中国人民解放军第二军医大学 | Application of Centella triterpenes in preparing products for improving cerebral apoplexy sequelae |
| US9155744B2 (en) | 2005-10-27 | 2015-10-13 | Lead Billion Limited | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
-
2004
- 2004-06-10 CN CNB2004100464873A patent/CN100531740C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9155744B2 (en) | 2005-10-27 | 2015-10-13 | Lead Billion Limited | Pharmaceutical composition and method for regenerating myofibers in the treatment of muscle injuries |
| CN102389437A (en) * | 2011-06-24 | 2012-03-28 | 中国人民解放军第二军医大学 | Application of Centella triterpenes in preparing products for improving cerebral apoplexy sequelae |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100531740C (en) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1457808A (en) | Iron scale dendrobium compound preposition and preparation and use | |
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1304039C (en) | Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use | |
| CN101033245A (en) | Preparation method and application of pedunculoside | |
| CN1919248A (en) | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease | |
| CN1582952A (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1686441A (en) | Chinese medicine capsule used for regulating immunity, its preparation method and use | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1919240A (en) | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases | |
| CN1679648A (en) | Mailuoning injection and its preparation and quality control | |
| CN1188406C (en) | Cattail pollen extract and preparation process and use thereof | |
| CN1582951A (en) | Health care products for auxiliary treatment of diseases of cardio-cerebral blood vessels | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1919239A (en) | Traditional medicine composition for treating cardiovascular and cerebrovascular diseases | |
| CN1895540A (en) | Medicinal composition for treating cardiovascular disease, its making method and use | |
| CN1883498A (en) | Compound puerarin for treating cardiovascular and cerebrovascular disease | |
| CN1803182A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1218701C (en) | Use of spirosterol type steroid saponin in preparing medicine for treating cardio-cerebral vascular disease | |
| CN1176697C (en) | Antisenility medicine composition and its prepn | |
| CN1283300C (en) | Chinese traditional medicine composition for treating diabetes and preparation method thereof | |
| CN1220510C (en) | Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method | |
| CN101032534A (en) | Method of preparing jiubiying total saponins and the application thereof | |
| CN1679810A (en) | Glucoside extracts from figwort roof, its making method and use in preparing medicines | |
| CN1582946A (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN1919252A (en) | Medicine for treating cardiovascular and cerebrovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090109 Address after: Room five, floor nine, building 83, Fuxing Road, 536, Beijing, Haidian District: 100856 Applicant after: the Academy of Military Medical Sciences Address before: 10, Chaoyang Avenue, Chaoyang District, Beijing, China: 100020 Applicant before: Cui Fugui |
|
| ASS | Succession or assignment of patent right |
Owner name: BEIJING SULIMAN PHARMACEUTICAL TECHNOLOGY CO., LTD Free format text: FORMER OWNER: CUI FUGUI Effective date: 20090109 |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090826 Termination date: 20170610 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |